FDA
-
-
-
-
-
-
-
Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
-
-
-
-
-
-
-
Actinium presents preclinical data for ATNM-400 prostate cancer therapy
-
-
-
-
-
-
-
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
-
-
-
-
-
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
-
-
-
-
-
-
-
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
-
-
-
-
-
-
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Res
-
-
-
-
-
-
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

